Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study
在 I/II 期 TROPION-PanTumor02 研究中,达托泊单抗 deruxtecan 用于既往接受过大量治疗的中国晚期或转移性三阴性乳腺癌患者。
期刊:Translational Breast Cancer Research
影响因子:1.400
doi:10.21037/tbcr-2025-1-81
Wang, Tao; Sun, Yuping; Chen, Wenyan; Li, Wei; Cheng, Jing; Li, Man; Yuan, Zhongyu; Qian, Jun; Wang, Kun; Wang, Shu; Xiong, Huihua; Yu, Zhigang; Wang, Xiaojia; Wu, Chunjiao; Maxwell, Micah J; Zhang, Biao; Liu, Chang; Zeng, Xiaoling; Jiang, Zefei